Precision Medicine

Labcorp's new direct-to-consumer genetic panel promises early risk detection. But does it create a new set of challenges for patients and doctors?

A new partnership between Lilac Biosciences and Soin Neuroscience aims to end the guesswork in pain management with groundbreaking RNA biomarker research.

A new pilot by Teal Health and UC Davis Health integrates an FDA-authorized self-collection kit into hospital workflows, targeting overdue patients.

With a mixed Q1 and a promise of a stronger second half, Myriad Genetics' upcoming earnings call will be a crucial test of its strategic health and pipeline.

Beam Therapeutics is set to unveil pivotal data for its AATD gene editor. Success could transform a disease and validate a multi-billion-dollar platform.

Life Science Connect's partnership with PMWC moves the 'Davos of Precision Medicine' beyond an annual event, creating a continuous digital and physical ecosystem.

Flatiron Health's landmark partnership with Scotland's NHS signals a new era where localized, real-world data becomes a critical asset in the global race for cancer cures.

A new AI-driven test from BRAINBox Solutions combines blood analysis and cognitive data, promising to finally replace guesswork in concussion diagnosis.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

A high-level Dubai summit unites tech, pharma, and policy to combat the GCC's escalating IBD crisis, heralding a new era of AI-driven care and IL-23 therapies.

A Boston biotech is making waves with a novel drug and a rapid-screening platform, a one-two punch designed to eliminate drug-resistant cancer stem cells.

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.

A $5M gift brings Mount Sinai into a unique global consortium, aiming to leverage precision medicine and AI to disrupt how we treat over 100 autoimmune diseases.

Lonza licenses its elite ADC tech to Engitix, a biotech targeting the hidden battlefield of the extracellular matrix. A quiet move with loud implications.

Beyond an impressive metric, DNAnexus's high customer trust validates its strategic pivot to become the essential AI backbone for the precision health revolution.

An upcoming FDA meeting on peptide compounding is more than a regulatory footnote. It's a battleground for the future of personalized and preventive care.

A new 'smart' brain implant is revolutionizing Parkinson's care in India, but as experts gather, the promise of this tech meets the reality of access.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

Precision IO Group is showcasing its AI-guided Epione robot and a vision for remote cancer surgery, aiming to erase geographic barriers to expert care.